Exogenous IL‐6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild‐type, African American PCa cells

African American men (AAM) are at higher risk of being diagnosed with prostate cancer (PCa) and are at higher risk of dying from the disease compared to European American men (EAM). We sought to better understand PCa molecular diversity that may be underlying these disparities. We performed RNA‐sequencing analysis on high‐grade PCa to identify genes showing differential tumor versus noncancer adjacent tissue expression patterns unique to AAM or EAM. We observed that interleukin‐6 (IL‐6) was upregulated in the nonmalignant adjacent tissue in AAM, but in EAM IL‐6 expression was higher in PCa tissue. Enrichment analysis identified that genes linked to the function of TP53 were overrepresented and downregulated in PCa tissue from AAM. These RNA‐sequencing results informed our subsequent investigation of a diverse PCa cell line panel. We observed that PCa cell lines that are TP53 wild‐type, which includes cell lines derived from AAM (MDA‐PCa‐2b and RC77T), did not express detectable IL‐6 mRNA. IL‐6 treatment of these cells downregulated wild‐type TP53 protein and induced mRNA and protein expression of the epigenetic reader methyl CpG binding domain protein 2 (MBD2), specifically the alternative mRNA splicing variant MBD2_v2. Further investigation validated that upregulation of this short isoform promotes self‐renewal and expansion of PCa cancer stem‐like cells (CSCs). In conclusion, this report contributes to characterizing gene expression patterns in high‐grade PCa and adjacent noncancer tissues from EAM and AAM. The results we describe here advance what is known about the biology associated with PCa race disparities and the molecular signaling of CSCs.

[1]  S. Gabriel,et al.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. , 2017, Cancer discovery.

[2]  M. Fischer,et al.  Census and evaluation of p53 target genes , 2017, Oncogene.

[3]  B. Bao,et al.  Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity , 2017, Scientific Reports.

[4]  E. Schaeffer,et al.  Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database , 2017, The Journal of urology.

[5]  C. Print,et al.  A Study of TP53 RNA Splicing Illustrates Pitfalls of RNA-seq Methodology. , 2016, Cancer research.

[6]  Q. Hu,et al.  NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis , 2016, Cell Discovery.

[7]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[8]  Xin Chen,et al.  Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer , 2016, Clinical Cancer Research.

[9]  J. Mefford,et al.  Mutational Landscape of Aggressive Prostate Tumors in African American Men. , 2016, Cancer research.

[10]  C. Burns,et al.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges , 2016, Oncogene.

[11]  E. Hurt,et al.  A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. , 2016, Cancer research.

[12]  B. Trock,et al.  Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. , 2015, European urology.

[13]  D. Levy,et al.  STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.

[14]  T. Rebbeck,et al.  Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Vessella,et al.  A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells , 2015, Cancer Immunology Research.

[16]  Ruth Etzioni,et al.  Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2015, JAMA oncology.

[17]  P. Brown,et al.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. , 2014, The Lancet. Oncology.

[18]  J. Korbel,et al.  Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer , 2014, International journal of cancer.

[19]  M. Rubin,et al.  Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men , 2014, Clinical Cancer Research.

[20]  Jignesh R. Parikh,et al.  Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. , 2014, Cell stem cell.

[21]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[22]  K. Kalland,et al.  Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. , 2013, Cancer research.

[23]  M. Cooperberg Re-examining racial disparities in prostate cancer outcomes. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[25]  Ian Chambers,et al.  A direct physical interaction between Nanog and Sox2 regulates embryonic stem cell self-renewal , 2013, The EMBO journal.

[26]  E. Plimack,et al.  AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. , 2013, The oncologist.

[27]  Aviv Regev,et al.  Corrigendum: Comparative analysis of RNA sequencing methods for degraded or low-input samples , 2013, Nature Methods.

[28]  I. Powell,et al.  Minireview: the molecular and genomic basis for prostate cancer health disparities. , 2013, Molecular endocrinology.

[29]  Wei Guo,et al.  Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145. , 2013, International journal of oncology.

[30]  Aliccia Bollig-Fischer,et al.  Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[31]  K. Hochedlinger,et al.  The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. , 2013, Cell stem cell.

[32]  R. Sinha,et al.  Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study , 2012, Cancer Causes & Control.

[33]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[34]  Yongmei Chen,et al.  Prostate cancer in men less than the age of 50: a comparison of race and outcomes. , 2011, Urology.

[35]  D. Tang,et al.  Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. , 2011, Biochimica et biophysica acta.

[36]  M. Hung,et al.  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[37]  J. Pinski,et al.  Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[38]  W. Sakr,et al.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.

[39]  Jing Ma,et al.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[41]  N. Maitland,et al.  Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[43]  S. Chua,et al.  Obesity, metabolic syndrome, and prostate cancer. , 2007, The American journal of clinical nutrition.

[44]  Pengbo Liu,et al.  Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.

[45]  Yajun Yi,et al.  Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.

[46]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[47]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[48]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Bono,et al.  Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.

[50]  S. Tonstad,et al.  Determinants of inflammatory markers in a bi-ethnic population. , 2011, Ethnicity & disease.

[51]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[52]  A. Gao,et al.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  R. Oyasu,et al.  Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.

[54]  Ministerial Meeting,et al.  Summary of the , 1994 .